Literature DB >> 9040451

Achievement and safety of a low blood pressure goal in chronic renal disease. The Modification of Diet in Renal Disease Study Group.

J M Lazarus1, J J Bourgoignie, V M Buckalew, T Greene, A S Levey, N C Milas, L Paranandi, J C Peterson, J G Porush, S Rauch, J M Soucie, C Stollar.   

Abstract

The Modification of Diet in Renal Disease Study showed a beneficial effect of a lower-than-usual blood pressure (BP) goal on the progression of renal disease in patients with proteinuria. The purpose of the present analyses was to examine the achieved BP, baseline characteristics that helped or hindered achievement of the BP goals, and safety of the BP interventions. Five hundred eighty-five patients with baseline glomerular filtration rate between 13 and 55 mL/min per 1.73 m2 (0.22 to 0.92 mL/s per 1.73 m2) were randomly assigned to either a usual or low BP goal (mean arterial pressure < or = 107 or < or = 92 mm Hg, respectively). Few patients had a history of cardiovascular disease. All antihypertensive agents were permitted, but angiotensin-converting enzyme inhibitors (with or without diuretics) followed by calcium channel blockers were preferred. The mean (+/- SD) of the mean arterial pressures during follow-up in the low and usual BP groups was 93.0 +/- 7.3 and 97.7 +/- 7.7 mm Hg, respectively. Follow-up BP was significantly higher in subgroups of patients with preexisting hypertension, baseline mean arterial pressure > 92 mm Hg, a diagnosis of polycystic kidney disease or glomerular diseases, baseline urinary protein excretion > 1 g/d, age > or = 61 years, and black race. The frequency of medication changes and incidence of symptoms of low BP were greater in the low BP group, but there were no significant differences between BP groups in stop points, hospitalizations, or death. When data from both groups were combined, each 1-mm Hg increase in follow-up systolic BP was associated with a 1.35-times greater risk of hospitalization for cardiovascular or cerebrovascular disease. Lower BP than usually recommended for the prevention of cardiovascular disease is achievable by several medication regimens without serious adverse effects in patients with chronic renal disease without cardiovascular disease. For patients with urinary protein excretion > 1 g/d, target BP should be a mean arterial pressure of < or = 92 mm Hg, equivalent to 125/75 mm Hg.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9040451     DOI: 10.1161/01.hyp.29.2.641

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  38 in total

1.  Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association.

Authors: 
Journal:  Heart       Date:  1998-12       Impact factor: 5.994

Review 2.  What is the optimal strategy to intensify blood pressure control and prevent progression of renal failure?

Authors:  M Epstein; S Tobe
Journal:  Curr Hypertens Rep       Date:  2001-10       Impact factor: 5.369

Review 3.  Epidemiology, diagnosis, and management of cardiac disease in chronic renal disease.

Authors:  M J Sarnak; A S Levey
Journal:  J Thromb Thrombolysis       Date:  2000-10       Impact factor: 2.300

4.  Oral supplement of six selective amino acids arrest progression renal failure in uremic patients.

Authors:  Hippocrates Yatzidis
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

5.  Queen Mary Utilization of Antihypertensive Drugs Study: use of antihypertensive drug classes in the hypertension clinic 1996-2004.

Authors:  Bernard M Y Cheung; Yuk Lin Wong; Chu Pak Lau
Journal:  Br J Clin Pharmacol       Date:  2005-07       Impact factor: 4.335

Review 6.  How aggressively should blood pressure be treated in renal transplant recipients?

Authors:  D K Klassen
Journal:  Curr Hypertens Rep       Date:  2000-10       Impact factor: 5.369

Review 7.  What is the ideal blood pressure goal for patients with stage III or higher chronic kidney disease?

Authors:  Yazan Khouri; Susan P Steigerwalt; Mershed Alsamara; Peter A McCullough
Journal:  Curr Cardiol Rep       Date:  2011-12       Impact factor: 2.931

Review 8.  Microalbuminuria in diabetes: focus on cardiovascular and renal risk reduction.

Authors:  George L Bakris; James R Sowers
Journal:  Curr Diab Rep       Date:  2002-06       Impact factor: 4.810

Review 9.  Combating diabetic nephropathy with drug therapy.

Authors:  D Martins; K Norris
Journal:  Curr Diab Rep       Date:  2001-10       Impact factor: 4.810

10.  Blood pressure control in diabetes: temporal progress yet persistent racial disparities: national results from the REasons for Geographic And Racial Differences in Stroke (REGARDS) study.

Authors:  Doyle M Cummings; Lisa Doherty; George Howard; Virginia J Howard; Monika M Safford; Valerie Prince; Brett Kissela; Daniel T Lackland
Journal:  Diabetes Care       Date:  2010-01-22       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.